# AVBP (Arrivent Biopharma, Inc.) - SEC EDGAR Financial Statements

> Arrivent Biopharma, Inc. reported $417.1M in total assets and a net loss of $169.1M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/AVBP
- Markdown: https://convexityos.com/fundamentals/AVBP.md
- SEC CIK: 0001868279
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:34 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001868279&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$181.0M | Operating profit |
| Net Income | FY 2025 | -$169.1M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$3.41 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $393.2M | Total debt: $256K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Research & Development | $153.4M | $79.00M | $64.88M |
| Total Operating Expenses | $177.5M | $94.31M | $74.59M |
| **Operating Income** | -$177.5M | -$94.31M | -$74.59M |
| **EBITDA** | -$180.6M | -- | -- |
| **Net Income** | -$166.3M | -$80.49M | -$69.33M |
| Basic EPS | -$4.32 | -$2.56 | -$32.38 |
| **Diluted EPS** | -$4.32 | -$2.56 | -$32.38 |
| Basic Shares Outstanding | 38.5M | 31.5M | 2.1M |
| Diluted Shares Outstanding | 38.5M | 31.5M | 2.1M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $5.00M | -- | -- | -- | -- | -- | -- | -- |
| Research & Development | $38.90M | $42.34M | $37.62M | $32.17M | $32.17M | $27.72M | $61.29M | $20.16M |
| Total Operating Expenses | $48.38M | $52.69M | $46.11M | $38.82M | $38.32M | $33.62M | $66.77M | $23.70M |
| **Operating Income** | -$43.38M | -$52.69M | -$46.11M | -$38.82M | -$38.32M | -$33.62M | -$66.77M | -$23.70M |
| **EBITDA** | -$44.03M | -$53.21M | -$46.67M | -- | -- | -- | -- | -- |
| **Net Income** | -$40.31M | -$49.89M | -$43.32M | -$35.54M | -$34.98M | -$31.40M | -$64.39M | -$20.63M |
| Basic EPS | -$0.81 | -$1.05 | -$0.96 | -- | -$0.83 | -$0.90 | -$1.90 | -- |
| **Diluted EPS** | -$0.81 | -$1.05 | -$0.96 | -- | -$0.83 | -$0.90 | -$1.90 | -- |
| Basic Shares Outstanding | 49.5M | 47.6M | 45.1M | -- | 41.9M | 35.0M | 33.9M | -- |
| Diluted Shares Outstanding | 49.5M | 47.6M | 45.1M | -- | 41.9M | 35.0M | 33.9M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $45.54M | $74.29M | $150.4M |
| Short-Term Investments | $267.3M | $144.6M | -- |
| **Cash & Short-Term Investments** | $312.8M | $218.9M | $150.4M |
| **Total Current Assets** | $332.9M | $227.0M | $160.0M |
| Long-Term Investments | -- | $47.68M | -- |
| Other Non-Current Assets | $190K | $126K | $107K |
| **Total Non-Current Assets** | $272K | $47.96M | $3.13M |
| **Total Assets** | $333.2M | $274.9M | $163.1M |
| Accounts Payable | $5.93M | $3.78M | $4.53M |
| **Total Current Liabilities** | $25.95M | $17.27M | $11.62M |
| **Total Non-Current Liabilities** | $0 | $14K | $177K |
| **Total Liabilities** | $25.95M | $17.29M | $11.80M |
| **Total Debt (incl. Leases)** | $14K | $176K | $317K |
| Common Stock | $4.0K | $3.0K | -- |
| Retained Earnings | -$404.6M | -$238.3M | -$157.8M |
| Accumulated Other Comp. Income | $14K | -$211K | -- |
| **Total Stockholders' Equity** | $307.2M | $257.7M | -$153.2M |
| Total Equity | $307.2M | $257.7M | -$153.2M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $113.6M | $154.7M | $62.10M | $45.54M | $112.7M | $112.8M | $49.87M | $74.29M |
| Short-Term Investments | $279.6M | $218.4M | $264.3M | $267.3M | $187.6M | $122.9M | $126.2M | $144.6M |
| **Cash & Short-Term Investments** | $393.2M | $373.1M | $326.4M | $312.8M | $300.3M | $235.7M | $176.1M | $218.9M |
| **Total Current Assets** | $416.6M | $394.2M | $348.7M | $332.9M | $321.2M | $250.1M | $185.8M | $227.0M |
| Long-Term Investments | -- | -- | -- | -- | $5.11M | $18.79M | $29.41M | $47.68M |
| Other Non-Current Assets | $134K | $134K | $156K | $190K | $180K | $479K | $176K | $126K |
| **Total Non-Current Assets** | $474K | $545K | $595K | $272K | $5.34M | $19.36M | $29.71M | $47.96M |
| **Total Assets** | $417.1M | $394.7M | $349.3M | $333.2M | $326.6M | $269.5M | $215.5M | $274.9M |
| Accounts Payable | $2.62M | $2.22M | $8.73M | $5.93M | $5.93M | $4.06M | $4.36M | $3.78M |
| **Total Current Liabilities** | -- | $27.84M | $25.00M | $25.95M | $21.56M | $19.64M | $12.95M | $17.27M |
| **Total Non-Current Liabilities** | -- | $33K | $320K | $0 | $0 | $0 | $0 | $14K |
| **Total Liabilities** | $23.61M | $27.88M | $25.32M | $25.95M | $21.56M | $19.64M | $12.95M | $17.29M |
| **Total Debt (incl. Leases)** | $256K | $351K | $419K | $14K | $56K | $98K | $138K | $176K |
| Common Stock | $5.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | $4.0K | $3.0K |
| Retained Earnings | -$538.2M | -$497.9M | -$448.0M | -$404.6M | -$369.1M | -$334.1M | -$302.7M | -$238.3M |
| Accumulated Other Comp. Income | -$466K | -$267K | -$270K | $14K | $206K | -$18K | -$17K | -$211K |
| **Total Stockholders' Equity** | $393.5M | $366.8M | $324.0M | $307.2M | $305.0M | $249.9M | $202.5M | $257.7M |
| Total Equity | $393.5M | $366.8M | $324.0M | $307.2M | $305.0M | $249.9M | $202.5M | $257.7M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$166.3M | -$80.49M | -$69.33M |
| Depreciation & Amortization | -$3.03M | -- | -- |
| Stock-Based Compensation | $12.52M | $3.21M | $895K |
| Change in Payables | $2.14M | -$751K | $1.38M |
| **Operating Cash Flow** | -$160.6M | -$70.21M | -$55.84M |
| Purchases of Investments | -$272.9M | -$194.2M | -- |
| Sales & Maturities of Investments | $201.7M | $1.70M | -- |
| **Investing Cash Flow** | -$71.23M | -$192.5M | -- |
| Common Stock Issued | $202.6M | $185.9M | -- |
| **Financing Cash Flow** | $203.1M | $186.6M | $42.86M |
| **Net Change in Cash** | -$28.75M | -$76.10M | -$12.98M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$40.31M | -$49.89M | -$43.32M | -$35.54M | -$34.98M | -$31.40M | -$64.39M | -$20.63M |
| Depreciation & Amortization | -$653K | -$515K | -$559K | -- | -- | -- | -- | -- |
| Stock-Based Compensation | $6.88M | $6.67M | $5.49M | $3.22M | $3.72M | $3.31M | $2.27M | $952K |
| Change in Payables | $400K | -$6.51M | $2.81M | -$8.0K | $1.87M | -$302K | $582K | -$865K |
| **Operating Cash Flow** | -$40.71M | -$39.58M | -$41.89M | -$30.66M | -$35.80M | -$26.12M | -$68.01M | -$16.15M |
| Purchases of Investments | -$126.2M | -$13.99M | -$64.38M | -$151.2M | -$90.37M | -$21.57M | -$9.82M | -- |
| Sales & Maturities of Investments | $65.57M | $60.06M | $67.97M | $79.98M | $39.61M | $35.48M | $46.64M | -- |
| **Investing Cash Flow** | -$60.65M | $46.07M | $3.58M | -$71.20M | -$50.76M | $13.91M | $36.82M | -- |
| Common Stock Issued | $59.66M | $85.23M | $54.72M | $34.66M | $86.12M | $75.34M | $6.52M | $0 |
| **Financing Cash Flow** | $60.26M | $86.09M | $54.87M | $34.73M | $86.47M | $75.11M | $6.76M | $55K |
| **Net Change in Cash** | -$41.10M | $92.58M | $16.56M | -$67.13M | -$93K | $62.90M | -$24.43M | -$208.6M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Return on Equity (ROE) | -54.1% | -31.2% | -- |
| Return on Assets (ROA) | -49.9% | -29.3% | -42.5% |
| Current Ratio | 12.83x | 13.14x | 13.76x |
| Quick Ratio | 12.06x | 12.67x | 12.94x |
| Debt to Equity | 0.00x | 0.00x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -43.0% | -44.6% | -44.8% | -54.1% | -49.6% | -54.8% | -62.9% | -31.2% |
| Return on Assets (ROA) | -40.5% | -41.5% | -41.6% | -49.9% | -46.4% | -50.8% | -59.1% | -29.3% |
| Current Ratio | -- | 14.16x | 13.95x | 12.83x | 14.90x | 12.74x | 14.34x | 13.14x |
| Quick Ratio | -- | 13.40x | 13.06x | 12.06x | 13.93x | 12.00x | 13.59x | 12.67x |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
